25 reports

  • JUN 01, 2018: SENSORION TO PRESENT SENS-401 AT THE 2018 BIO INTERNATIONAL CONVENTION
  • JAN 24, 2018: SENSORION ANNOUNCES MULTIPLE POSTER PRESENTATIONS AT THE ARO 2018 MIDWINTER MEETING

JUN ##, 2017: SENSORION TAKES A KEY STEP TOWARDS PHASE ## WITH SENS-## THANKS TO THE POSITIVE RESULTS OBTAINED IN THE PHASE ## CLINICAL TRIAL Sensorion, a biotech company specializing in the treatment of inner ear diseases, announces the positive results of the phase

  • Ear Disease
  • Therapy
  • World
  • Product Initiative
  • Sensorion S.A.
  • four centers in the US.
  • FEATURED NEWS & PRESS RELEASES

Otonomy Inc (Otonomy) develops and markets treatments for diseases and disorders of the ear.

  • Ear Disease
  • United States
  • World
  • Product Initiative
  • Auris Medical Holding AG
  • Sound Pharmaceuticals Inc
  • Oct 03, 2017: Sound Pharmaceuticals announces positive Phase 1b results and the start of a Phase 2b clinical trial in Menieres Disease

Patients will receive an administration of OTO-## in one ear prior to each of the first three cisplatin treatment cycles, with the contralateral ear as an untreated control.

  • Ear Disease
  • Pharmaceutical
  • United States
  • Product Initiative
  • Otonomy, Inc.

JUN ##, 2017: SENSORION TAKES A KEY STEP TOWARDS PHASE ## WITH SENS-## THANKS TO THE POSITIVE RESULTS OBTAINED IN THE PHASE ## CLINICAL TRIAL Sensorion, a biotech company specializing in the treatment of inner ear diseases, announces the positive results of the phase

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • Molecular Diagnostics
  • Therapy
  • Sensorion S.A.
  • Meniere Disease - Pipeline by Sound Pharmaceuticals Inc, H1 2018
  • Oct 03, 2017: Sound Pharmaceuticals announces positive Phase 1b results and the start of a Phase 2b clinical trial in Menieres Disease

Patients will receive an administration of OTO-## in one ear prior to each of the first three cisplatin treatment cycles, with the contralateral ear as an untreated control.

  • Ear Disease
  • Pharmaceutical
  • United States
  • Product Initiative
  • Otonomy, Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status and sponsor type.

  • Ear Disease
  • Therapy
  • World
  • Product Initiative
  • Auris Medical Holding AG
  • FEATURED NEWS & PRESS RELEASES

These highly ototoxic medications can result in permanent, and often progressive inner ear disease.

  • Ear Disease
  • Therapy
  • United States
  • World
  • Product Initiative
  • May 22, 2018: Sensorion Appoints Professor Christine Petit, MD, PhD as Chair of its Scientific Advisory Board
  • Sensorion Raises USD9 Million in IPO

This successful transformation has produced a unique screening platform in the highpotential inner-ear diseases sector and its two first drug candidates, SENS-## in phase ## and SENS-## in phase ##.

  • Clinical Trial
  • Ear Disease
  • Pharmaceutical
  • France
  • Sensorion S.A.
  • 1.1 Hearing Loss

It can occur in both or one ear of a person and can be temporary or permanent.

  • Ear Disease
  • World
  • Forecast
  • Market Size
  • Sonova Holding AG
  • Target
  • LATEST CLINICAL TRIALS NEWS ON MENIERE DISEASE

Currently, there are no FDA approved drug treatments for MD, or any other inner ear disease.

  • Clinical Trial
  • Ear Disease
  • World
  • Product Initiative
  • Otonomy, Inc.
  • EXAMPLES OF OUTER, MIDDLE AND INNER EAR DISEASES
  • 4.3.3. GENE THERAPY/ STEM CELLS FOR INNER EAR DISEASES

THE MAJORITY GETS AFFECTED BY MENIERE' S DISEASE ONLY IN ONE OF THE TWO EARS.

  • Ear Disease
  • United States
  • AudioCure Pharma GmbH
  • Autifony Therapeutics Limited
  • Cochlear Limited
  • Sensorion's Key Drug Pipeline (2017)

Otividex Ménière' s Disease Phase ## Intratympanic Synphora AB Latanoprost Ménière' s Disease Phase ## Intratympanic Sensorion SA SENS-## AUV Phase ## Oral Auris Medical Holding Ag AM-## Ménière' s Disease Phase ## Intranasal Sound Pharmaceutica

  • Ear Disease
  • Therapy
  • Company
  • Forecast
  • Auris Medical Holding AG
  • Otonomy Inc - Business Description

Overview HEAD OFFICE Otonomy Inc ## Executive Drive San Diego CA ## United States Tel: +## ## ## Fax: +## ## ## Otonomy Inc - Locations And Subsidiaries Otonomy Inc (Otonomy) develops and markets treatments for diseases and disorders of the ear.

  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • United States
  • Company Financials
  • Otonomy, Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status and sponsor type.

  • Drug Development
  • Ear Disease
  • Hospital
  • World
  • Product Initiative
  • Oct 03, 2017: Sound Pharmaceuticals announces positive Phase 1b results and the start of a Phase 2b clinical trial in Menieres Disease
  • 09/25/2017: Sound Pharmaceuticals initiates STOP Ototoxicity Study in Cystic Fibrosis

The company intends to use the proceeds to develop treatments for inner ear disease.

  • Ear Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Deals & Alliance
  • Clinical Trial profile. 35 Trial Title
  • LATEST CLINICAL TRIALS NEWS ON HEARING DISORDERS

Sensorion, a biotech company specializing in the treatment of inner ear diseases, announces the positive results of the phase ## clinical trial of SENS-## treatment of inner ear lesions.

  • Clinical Trial
  • Ear Disease
  • Therapy
  • World
  • Product Initiative
  • Clinical Trial profile. 121 Trial Title
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status and sponsor type.

  • Clinical Trial
  • Ear Disease
  • Hospital
  • Therapy
  • World
  • Clinical Trial profile. 31 Trial Title
  • Clinical Trial Profile Snapshots

PROPORTION OF ACUTE SENSORINEURAL HEARING LOSS TO EAR NOSE THROAT DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), PROPORTION OF ACUTE SENSORINEURAL HEARING LOSS TO EAR NOSE THROAT DISORDERS CLINICAL TRIALS, E## COUNTRIES (%), In total there were four clinical trials conducted on Acute

  • Ear Disease
  • Hospital
  • Therapy
  • World
  • Product Initiative
  • OR-102 - DRUG PROFILE

It was also under development for the treatment of myocardial infarction, organ transplantation, Meniere disease and Parkinson' s disease (cell transplantation).

  • Ear Disease
  • Therapy
  • World
  • Product Initiative
  • Auris Medical Holding AG

The report focuses on drugs and therapies being evaluated for Ear Infections treatment in active clinical development phases including phase ##, phase ##, phase ## and phase ## clinical trials.

  • Clinical Trial
  • Ear Disease
  • Ear, Nose, And Throat Medicine
  • Infectious Disease
  • Pathology

" If successful then we will have a future therapy that we can adapt to combat other diseases caused by bacteria that breed in the nasal pathway such as pneumonia and ear disease.

  • Ear Disease
  • Pharmaceutical
  • Therapy
  • United Kingdom
  • BioInvent

Major driving factors for the market growth are increasing number of patients suffering from hearing problems, ear infection and other diseases have boosted the growth of the market.

  • Ear Disease
  • North America
  • United States
  • World
  • Advanced Bionics Corporation
  • R&D Progress
  • R&D Progress

THE INVENTION RELATES TO METHODS AND KITS USEFUL FOR PROVIDING NEUROPROTECTION TO NEURONS IN THE INNER EAR AND TO METHODS OF TREATING INNER EAR DISEASES AND DISORDERS, INCLUDING TINNITUS AND MENIERE' S DISEASE.

  • Ear Disease
  • United States
  • World
  • Product Initiative
  • Quark
  • Palau Pharma, S.A.

(Sensorion) is a biopharmaceutical company that develops treatment for the inner ear diseases.

  • Ear Disease
  • Medical Biotechnology
  • Pharmaceutical
  • Therapy
  • Product Initiative
  • Clinical Trial profile. 20 Trial Title
  • Clinical Trial Profile Snapshots

The prominent features of this report are - ##.

  • Ear Disease
  • Therapy
  • World
  • Product Initiative
  • Auris Medical Holding AG